BioSpace News Archive

Be Biopharma (“Be Bio”) today announced the appointment of John Mayfield, Ph.D., to the newly created position of Chief Business Officer.

Takeda today announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA ® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in individuals from four years of age in the European Union (EU).i QDENGA should be used in accordance with official recommendations.

KalVista Pharmaceuticals, Inc. today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2022.

Sosei Group Corporation, the world leader in G protein-coupled receptor focused structure-based drug design and development, announces it has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, UK and KU Leuven, Belgium.

Addex Therapeutics announced that the research term of its collaboration agreement with Indivior PLC for the discovery of novel oral gamma-aminobutyric acid subtype B positive allosteric modulator drug candidates for the treatment of substance use disorder has been extended until June 30, 2023.

iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, announces the first patient has been dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.

Alvotech announced that trading in its shares will move from the Nasdaq Iceland First North Growth market to the Nasdaq Iceland Main Market, starting December 8, 2022.

Clinigen Limited is pleased to notethe announcement of top-line results from MIROCALS a phase 2b randomised placebo-controlled trial investigating the efficacy and safety of low dose interleukin-2 for controlling neuro-inflammation in newly-diagnosed patients with amyotrophic lateral sclerosis.

The Native Antigen Company announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein.

Dantari, Inc., a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases, announced its emergence from stealth mode with $47 million Series A financing.